TTC6 Inhibitors
TTC6 inhibitors encompass a range of chemicals that target various signaling pathways and biochemical processes to reduce the activity of TTC6. One such inhibitor is a potent kinase antagonist that disrupts a broad spectrum of kinases, possibly affecting the phosphorylation state of TTC6, thus leading to a decrease in its functional activity. Other inhibitors specifically target the phosphoinositide 3-kinases (PI3K) or the mammalian target of rapamycin (mTOR) pathways, which are crucial for the activation and stability of proteins involved in TTC6-mediated signaling. By impeding these pathways, these inhibitors could reduce the levels and effect of TTC6. Additionally, some inhibitors act on calcineurin and the MAPK pathway by obstructing the activation of kinases upstream of ERK or the p38 MAPK, potentially impacting TTC6 function that may be modulated by these signaling cascades.
Further inhibitory actions are achieved through chemicals that disrupt the c-Jun N-terminal kinase (JNK) pathway, leading to the prevention of phosphorylation events that are critical for TTC6's activity or stability. Proteasome inhibitors play a role by obstructing the degradation of ubiquitinated proteins, leading to the accumulation of misfolded or damaged TTC6, thus inhibiting its normal function. Furthermore, compounds that inhibit the activity of EGFR kinase or alter chromatin structure and gene expression are part of the TTC6 inhibitors. The former could affect signaling pathways that regulate TTC6's activity or expression, while the latter could lead to changes in the expression of genes involved in TTC6 regulation or function.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
A potent kinase inhibitor that targets a wide range of kinases. Staurosporine's inhibition of certain kinases could reduce the phosphorylation levels of TTC6, leading to its functional inhibition. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A specific inhibitor of phosphoinositide 3-kinases (PI3K). By inhibiting PI3K, LY 294002 could prevent the activation of downstream targets that may be necessary for TTC6-mediated signaling. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that can suppress the mTOR signaling pathway. Since mTOR pathways could regulate the stability and translation of proteins like TTC6, rapamycin may lead to a decrease in TTC6 levels. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $63.00 $92.00 $250.00 $485.00 $1035.00 $2141.00 | 69 | |
Inhibits calcineurin. By inhibiting calcineurin, Cyclosporin A could prevent the dephosphorylation and activation of substrates that are essential for TTC6 function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
An inhibitor of MEK, which is upstream of ERK in the MAPK pathway. Inhibition of MEK by PD 98059 would prevent ERK activation, potentially affecting TTC6 function if TTC6 is modulated by the MAPK pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A p38 MAPK inhibitor that could impede the p38 MAPK signaling pathway. This inhibition could lead to reduced TTC6 activity if TTC6 is involved in stress response pathways regulated by p38 MAPK. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of the c-Jun N-terminal kinase (JNK) signaling pathway. By inhibiting JNK, SP600125 could prevent phosphorylation events important for TTC6 activity or stability. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A proteasome inhibitor that prevents the degradation of ubiquitinated proteins. Bortezomib could cause the accumulation of misfolded or damaged TTC6, potentially disrupting its normal function. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
A proteasome inhibitor. MG-132 could lead to the accumulation of misfolded TTC6 proteins, inhibiting their proper function. | ||||||
WZ 4002 | 1213269-23-8 | sc-364655 sc-364655A | 10 mg 50 mg | $180.00 $744.00 | 1 | |
An inhibitor of the EGFR kinase. By blocking EGFR kinase activity, WZ 4002 could influence signaling pathways that regulate TTC6 activity or expression. | ||||||